Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone301-556-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$160.57 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Intrexon (NASDAQ:XON) Frequently Asked Questions
What is Intrexon's stock symbol?
Intrexon trades on the NASDAQ under the ticker symbol "XON."
How were Intrexon's earnings last quarter?
Intrexon Corp (NASDAQ:XON) posted its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company earned $35.99 million during the quarter, compared to analysts' expectations of $29.62 million. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. Intrexon's quarterly revenue was down 20.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.51) earnings per share. View Intrexon's Earnings History.
When is Intrexon's next earnings date?
What price target have analysts set for XON?
3 brokerages have issued twelve-month price objectives for Intrexon's shares. Their forecasts range from $6.00 to $43.00. On average, they expect Intrexon's stock price to reach $19.67 in the next year. This suggests a possible upside of 278.9% from the stock's current price. View Analyst Price Targets for Intrexon.
What is the consensus analysts' recommendation for Intrexon?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.
What are Wall Street analysts saying about Intrexon stock?
Here are some recent quotes from research analysts about Intrexon stock:
- 1. Northland Securities analysts commented, "We believe the company will spin-off its assets as the company has backed away from its target cash burn goal of $70M." (8/12/2019)
- 2. According to Zacks Investment Research, "We are positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations and joint ventures. Intrexon's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates in partnership deals, targeting a broad range of diseases including cancer. Additionally, the company announced the formation of a wholly-owned subsidiary, Precigen, Inc. as part of its structural alternatives, so that it can take better decisions regarding its health business. However, the company largely depends on ECCs and license, and collaboration deals for revenues. Any unfavorable outcome from the development of these might be a major setback and hurt the company’s prospects too. Though, estimates have remained stable ahead of its Q4 earnings release, Intrexon has a positive record of earnings surprises in recent quarters." (1/26/2019)
Has Intrexon been receiving favorable news coverage?
Press coverage about XON stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Intrexon.
Who are some of Intrexon's key competitors?
Some companies that are related to Intrexon include Medpace (MEDP), National Research (NRC), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), HedgePath Pharmaceuticals (HPPI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX) and Vitality Biopharma (VBIO).
What other stocks do shareholders of Intrexon own?
Who are Intrexon's key executives?
Intrexon's management team includes the folowing people:
- Mr. Randal J. Kirk, Chairman & CEO (Age 65)
- Mr. Rick L. Sterling, Chief Financial Officer (Age 54)
- Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Robert F. Walsh III, Sr. VP of Energy & Fine Chemicals Platforms (Age 60)
- Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 46)
Who are Intrexon's major shareholders?
Intrexon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include NJ State Employees Deferred Compensation Plan (0.01%) and Stephens Inc. AR (0.01%). Company insiders that own Intrexon stock include Andrew J Last, Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon.
Which major investors are selling Intrexon stock?
XON stock was sold by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan and Stephens Inc. AR. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon.
How do I buy shares of Intrexon?
Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intrexon's stock price today?
One share of XON stock can currently be purchased for approximately $5.19.
How big of a company is Intrexon?
Intrexon has a market capitalization of $841.14 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon.
What is Intrexon's official website?
How can I contact Intrexon?
Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]
MarketBeat Community Rating for Intrexon (NASDAQ XON)
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe XON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XON will underperform the S&P 500 over the long term. You may vote once every thirty days.
